Biomerics Launches Interventional Medical Plastics Division with Acquisition of Dependable Plastics

Biomerics, the leading vertically integrated medical device contract manufacturer in the interventional device market, announced the acquisition of Dependable Plastics and creation of a new division — Biomerics Interventional Medical Plastics (IMP) Division. Biomerics’ IMP Division with operations in Fairfield, California, and Salt Lake City, Utah is a full-service plastics component supplier to the interventional device market with a focus on robotic-assisted surgery.

Founded in 1983 by Harry Marquez and Emil Eger, Dependable Plastics is an industry leader in advanced thermoforming, liquid cast resin molding, and additive manufacturing. These capabilities, combined with Biomerics injection molding operations, will make Biomerics IMP a full-service plastics component supplier to the interventional markets. The acquisition marks Biomerics’ second expansion into California, complementing their Micromachining Center of Excellence in Santa Clara, CA.

“In support of our leading customers, Biomerics is excited to launch our Interventional Medical Plastics Division,” stated Travis Sessions, CEO of Biomerics. “This acquisition expands our plastic component capabilities for the interventional robotic surgical market. We are excited to welcome the Dependable Plastics employees to the Biomerics team.”

Biomerics IMP offers a variety of plastic component technologies including liquid cast resin, advanced thermoforming, injection molding, and innovative additive (printed part) manufacturing. The division also offers secondary processes including pad printing, painting, shielding, and sub-assemblies. Biomerics provides design, development, and production services to help customers develop next generation robot-assisted surgery systems.

Biomerics IMP will be led by Brett Poole who will transfer responsibilities from the founders over the rest of the year. “I look forward to joining Biomerics to lead the Dependable Plastics team,” stated Brett Poole, President of Biomerics IMP. “I look forward to continuing the 40-year history of excellence and integrating these new capabilities into Biomerics.

Chris Richardson, VP of Sales and Marketing, agreed: “We are delighted to join forces with the Dependable Plastics team carrying on a legacy of superior service. Biomerics IMP, combined with our other divisions, makes Biomerics the single-source vertically integrated solution for interventional market. We look forward to continuing our deep relationship with our industry leading customers”.

Travis Sessions concluded, “The Biomerics IMP Division was created to integrate Biomerics’ various plastics manufacturing component technologies to enable rapid design, development, and manufacture of plastics components for the robotic and interventional markets. We look forward to partnering with our customers to make important advances in patient care.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”